Nuvectis Pharma Inc Total Liabilities
Nuvectis Pharma Inc total liabilities. Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) has total liabilities worth $13.29 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Nuvectis Pharma Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Nuvectis Pharma Inc (2020–2025)
Total liabilities of Nuvectis Pharma Inc from 2020 to 2025. This chart illustrates how Nuvectis Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Nuvectis Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Nuvectis Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Carasso
TA:CRSO
|
Israel | ILA9.35 Billion |
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
China | CN¥231.65 Million |
|
Stingray Group Inc
TO:RAY-A
|
Canada | CA$866.47 Million |
|
Siantar Top Tbk
JK:STTP
|
Indonesia | Rp651.07 Billion |
|
Science Environmental Protection Co. Ltd. A
SHG:688480
|
China | CN¥817.92 Million |
|
Prashkovsky
TA:PRSK
|
Israel | ILA5.04 Billion |
|
Wereldhav B-Sicafi
BR:WEHB
|
Belgium | €460.95 Million |
|
Walton Advanced Engineering Inc
TW:8110
|
Taiwan | NT$4.31 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Nuvectis Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Nuvectis Pharma Inc.
Liquidity & Leverage Metrics
Nuvectis Pharma Inc Total Liabilities Ratios Explained
Nuvectis Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuvectis Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuvectis Pharma Inc (2020–2025)
The table below shows the annual total liabilities of Nuvectis Pharma Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $13.30 Million | +49.49% |
| 2024-12-31 | $8.89 Million | +27.35% |
| 2023-12-31 | $6.98 Million | +12.90% |
| 2022-12-31 | $6.19 Million | -64.98% |
| 2021-12-31 | $17.66 Million | +176550.00% |
| 2020-12-31 | $10.00K | -- |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was forme… Read more